Background. The matricellular protein SPARC (secreted
to modulate expression of transforming growth factor-␤ scribes the expression of SPARC during human renal development, in normal kidneys and during renal allograft rejection.
(TGF-␤), its ability to inhibit cell proliferation, and its Methods. A total of 60 renal specimens, including normal anti-adhesive properties with respect to some cell types areas from tumor nephrectomies (N ϭ 24), fetal kidneys (N ϭ in culture [1, 2] . Of particular interest are putative roles 27 ) and explanted renal allografts (N ϭ 9), were included in the for SPARC in organ development [3] [4] [5] and wound restudy. SPARC protein was localized by immunohistochemistry using two different antibodies. On consecutive sections SPARC pair [2, 6] , as studies have demonstrated that this molemRNA was detected by in situ hybridization.
cule promotes angiogenesis, as well as the deposition and
Results. In the normal adult kidney SPARC protein was exorganization of extracellular matrix molecules including pressed by visceral and parietal epithelial cells, collecting duct several members of the collagen family [2, 3, 7] . The epithelium (CD), urothelium, smooth muscle cells of muscular arteries and focally in interstitial cells. During renal developmechanisms by which these processes occur are not well ment immature glomeruli demonstrated a polarized SPARC understood. However, the crystal structure of two modexpression in visceral epithelial cells at their surface abutting ules of the SPARC molecule has been determined and the capillary basement membranes. In the fully differentiated key structural domains thought to be responsible for glomeruli the expression pattern mirrored that of the adult kidney. Furthermore, SPARC was abundantly expressed by derthese activities have been defined [8, 9] . including chronic cyclosporine nephropathy, renal ablaConclusion. These studies co-localize SPARC to several sites tion, passive Heymann nephritis, diabetes, and the angioof renal injury previously shown to be sites of PDGF B-chain tensin II infusion model [10] [11] [12] [13] [14] . A common finding in expression and/or activity. We speculate that SPARC could function as an accessory molecule in chronic PDGF-mediated sclethese models is that SPARC is expressed by the ␣-smooth rosing interstitial and vascular injury. SPARC localization to muscle actin expressing interstitial fibroblasts ("myofiglomerular epithelial cells corresponds to similar findings in broblasts") that participate in tubulointerstitial injury, rodents, and may reflect its role in cell adhesion and /or regulaand that SPARC expression is associated with collagen tion of cell shape.
I expression in such areas of injury. An important link between SPARC expression and the deposition of extra-Up-regulated SPARC expression in glomerular epithelial cells also has been linked to immunologically me- 2002 by the International Society of Nephrology diated injury such as passive Heymann nephritis [10] .
noblotting of synthetic SPARC peptides. The epitope recognized by this monoclonal IgG was found to require Therefore, it is of interest to know where SPARC is expressed in the human kidney. In one broad survey of amino acids 5-23 of the mature protein [18] . MAB-2 is a murine monoclonal IgG1 antibody directed against human tissues, SPARC expression was localized to several mesenchymal cell types, including fibrocytes and vashuman SPARC peptide 1. tope of human monocytes and macrophages was used in methyl Carnoy's-fixed tissues [22] . This antibody has METHODS been shown to recognize cells of monocyte/macrophage Tissue lineage in fixed tissues with no loss of sensitivity compared with frozen tissue specimens [22] . The specificity Normal human renal tissue (N ϭ 24) was obtained from kidneys surgically excised because of the presence of this antibody has been established by studies of transfected and untransfected cell lines and by immunocytoof a localized neoplasm. Tissues utilized for this study were obtained from macroscopically normal portions of chemical surveys of numerous cell lines and examples of neoplastic and non-neoplastic hematopoietic tissues, kidney located at some distance from the neoplastic process. Allograft kidneys (N ϭ 9) excised for irreversible as previously described [22] . PDGF A. Anti-PDGF A chain (Santa Cruz Biotechrejection were used as an example of inflammatory and advanced fibrosis injury. Human fetal kidneys (N ϭ 27) nology, Santa Cruz, CA, USA) is an affinity-purified rabbit polyclonal antibody raised against a 30 amino acid were obtained from tissue examined after therapeutic abortions.
peptide corresponding to the amino terminus of the human PDGF-A chain. It has been characterized by WestTissues were fixed in methyl Carnoy's fixative (60% methanol, 30% chloroform, 10% acetic acid) or in 10% ern blot and peptide absorption [23] and its specificity demonstrated in human kidneys [23, 24] . neutral buffered formalin for at least 12 hours, processed, paraffin embedded and sectioned using conventional PDGF B. Murine monoclonal antibody PG7-007 (provided by Mochida Pharmaceutical, Tokyo, Japan) has techniques. Some tissues from the nephrectomy specimens also were snap frozen and utilized for RNA prepabeen characterized by Western blotting of whole kidney extracts [24] and has been previously shown to specifiration.
These studies were performed under approval from cally recognize PDGF-B chain in methyl Carnoy's fixed tissue [21, 24] . the University of Washington Human Subjects Division (Approval #01-8008-E-01) under conditions of tissue an-PDGF ␣-receptor. Anti-PDGF ␣-receptor (A951; Santa Cruz Biotechnology) is an affinity-purified rabbit polyonymization, whereby all study investigators remain masked to the specific identity of patients from whom clonal antibody. This antibody has been characterized by Western blotting [25] and has been shown to specifically tissue sections were obtained. Accordingly, parameters of clinical outcome related to SPARC expression could immunolabel PDGF ␣-receptor in methyl Carnoy's fixed tissue [25, 26] . not be evaluated.
Antibodies

Western blotting
Western blotting was performed using lysates from SPARC. Anti-SPARC (AON-5031) is a murine monoclonal antibody directed against human, rat, and bovine whole human kidneys or recombinant SPARC protein.
Lysates were fractionated on a 12% polyacrylamide elec-SPARC/osteonectin (Haematologic Technologies, Essex Junction, VT, USA). This antibody was characterized trophoretic gel that contained 0.1% SDS and then transferred onto nitrocellulose membranes by electroblotting. by Western immunoblotting of purified, recombinant human SPARC [16, 17] . Specific immunoreaction was local-
The blots were blocked with 5% bovine serum albumin (BSA) in phosphate buffered saline (PBS) for one hour ized to a 33 kD band of the non-glycoslyated recombinant protein and a 43 kD band in tissue [12] [20, 27] . Briefly, sections were deparng primer and 20 units of M-MLV RT in a total volume of 20 L. The reactions were allowed to proceed for 45 affinized in xylene and rehydrated in graded ethanols. Endogenous peroxidase was blocked by incubation in minutes at 37ЊC and then the enzyme was inactivated by incubation at 65ЊC for five minutes. 3% hydrogen peroxide and non-specific binding was blocked by incubation in 10% normal goat serum. The
The synthesized first strand cDNA from the RT reaction was amplified by PCR. The reaction mixture consections were then incubated for one hour with the primary antibody. Following washes in PBS, the sections tained 60 pmol of each primer, 10 mmol/L Tris-HCl, 1.5 mmol/L MgCl 2 , 500 mmol/L KCl, and 200 mol/L were sequentially incubated with biotinylated second antibodies (Vector Labs), the ABC-Elite reagent (Vector 4dNTP. The PCR reactions were performed using a PTC 100 (MJ Research, Inc., Watertown, MA, USA) temperLabs) and finally 3,3Ј-diaminobenzidine (with nickel chloride enhancement) was used as the chromogen. The secature cycler. After a five minute incubation at 85ЊC, 2.5 U Taq DNA polymerase (Boehringer Mannheim, tions were counterstained with methyl green, dehydrated and cover slipped.
Indianapolis IN, USA) were added to each tube, followed by a denaturation step at 94ЊC for one minute, an Specificity controls for the labeling procedures included substitution of irrelevant non-immune mouse IgG annealing step at 64ЊC for one minute and an extension step at 72ЊC for one minute. The reaction tubes were or rabbit sera for the primary antibodies, and pre-absorption of the antibody with recombinant protein (for AONthen cycled 35 times for thirty seconds at 94ЊC, followed by one minute at 64ЊC and one minute at 72ЊC. After a 5031), followed by the otherwise identical immunocytochemical procedures.
final extension step at 72ЊC for ten minutes, the tubes were held at 4ЊC. A 10 L aliquot of the PCR products Double label immunohistochemistry was fractionated on a 1% agarose gel, stained with ethidium bromide and visualized with an ultraviolet transilluSlides were first immunostained as described above using MAB-2 or CD68 and DAB without nickel chloride minator. The expected 427 bp product was obtained from two different RNA preparations using both the random enhancement to visualize either SPARC or monocytes/ macrophages, respectively, with a brown reaction prodhexamer primer and the 3Ј SPARC primer. Probe preparation. The product from the PCR reacuct. Following a PBS rinse and further block with 3% hydrogen peroxide, the slides were incubated sequention was cloned using the pGEM-T Vector System (Promega, Madison, WI, USA). The ligation reaction mixtially with 1A4 or MAB-2 (to localize alpha smooth muscle actin or SPARC, respectively) overnight at 4ЊC, ture contained 2 Weiss Units of T4 DNA Ligase, 50 ng pGEM-T Vector DNA, 30 mmol/L Tris-HCl (pH 7.5), HRP conjugated anti-mouse antibody (Dako, Carpinteria, CA, USA) and then developed with the True Blue 10 mmol/L MgCl 2 , 10 mmol/L DTT, 1 mmol/L adenosine 5Ј-triphosphate (ATP) and 25 ng SPARC PCR product substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA) to give a blue color reaction.
DNA. The reaction was incubated for two hours at 15ЊC and then transformed into Maximum Efficiency DH5␣ In situ hybridization competent E. coli cells (Gibco BRL). After plating on LB/amp/IPTG/X-gal plates, white colonies were selected Primer design. Two oligonucleotide primers were designed to be used for the amplification of human SPARC.
and used in a standard plasmid miniprep procedure. After restriction enzyme mapping, one clone was seThe 3Ј primer (5Ј-GGAGAGGTACCCGTCAATGG-3Ј) spans the eighth intron/exon junction (bases 374-395) of lected as it contained a single insert of the SPARC cDNA. The presence of the insert was confirmed by the human SPARC cDNA and the 5Ј primer (5Ј-CGA GTTTGAGAAGGTGTGCAGC-3Ј) spans the fifth indideoxy sequencing of both strands from the T7 and SP6 promoters of the pGEM-T vector. This construct tron/exon junction (bases782-801). The primers were synthesized by Bio-Synthesis, Inc. (Lewisville, TX, USA).
was linearized and transcribed into a riboprobe using reagents from Promega (Madison, WI, USA), except RNA preparation, reverse transcription (RT) and poly- In addition, non-radioactive in situ hybridization was polymerase. After 75 minutes at 37ЊC, the template DNA was digested by adding 1 U of DNAse (Promega) and performed. The slides were prepared as above and the hybridization was carried out using a digoxigenen-labeled riincubating at 37ЊC for an additional 15 minutes. Free nucleotides were separated with a Sephadex G-50 colboprobe (Boehringer Mannheim, Indianapolis, IN, USA). The slides were washed as above and the probe was deumn. Probes were used within 48 hours.
Sequencing of probe and verification of identity. One tected using horseradish peroxidase labeled anti-digoxigenin antibody (Boehringer Mannheim), followed by amnanogram of the insert DNA cDNA fragment of the human SPARC/pGEM-T plasmid was characterized by plification using the TSA-Indirect Kit (NEN) and then DAB with nickel enhancement to give a black reaction Taq polymerase dye terminator cycle sequencing (Perkin Elmer Corporation, Foster City, CA, USA). Annealing product. The slides were then counterstained with methyl green and cover slipped. of template to oligonucleotide primers was achieved through the use of SP6 and T7 primers specific for the PGEM-T plasmid. Both strands of the insert were com-RESULTS pletely sequenced. This SPARC DNA cDNA fragment, Histologic characterization of renal tissues obtained from the uninvolved kidney tissue of a single patient with a localized neoplasm, was found to be 427
Developing kidneys were obtained from fetuses of estimated 57 to 120 days gestational age, as previously bp in length. The fragment was 99% identical (423/427 bp) with the coding region of human SPARC cDNA described. These kidneys demonstrated age appropriate features of glomerulogenesis and tubulogenesis, and (accession #Y00755 and #J03040). The lack of complete identity was due to differences at the position of the uniformly lacked features of maldevelopment such as dysplasia, scarring, or cyst development. Mature renal wobble base of 4 codons. These differences were found in exon 8 and correspond to the following amino acids:
tissues obtained from nephrectomy specimens demonstrated focal changes typically associated with aging, in-#183, CAT (His) to CAC (His); #190, GAG (Glu) to GAC (Glu); #212, TTC (Phe) to TTT (Phe); and #213, cluding focal global glomerulosclerosis involving less than 10% of glomeruli sampled, mild patchy interstitial CCT (Pro) to CCC (Pro). The insert of this recombinant plasmid corresponds to amino acids 85 through 226 of fibrosis and associated tubular atrophy, and focal mild intimal sclerosis involving muscular arteries. Pathologic the human SPARC protein sequence.
In situ hybridization. Fetal and adult kidney tissue features characteristic of other specific glomerular, tubulointerstitial, or vascular injuries were not identified in that had been fixed in 10% formalin and embedded in paraffin was deparaffinized following standard protocol.
this sample. Kidneys with chronic allograft nephropathy demonstrated more extensive global glomerulosclerosis, The sections were washed with 0.5ϫ standard saline citrate (SSC; 1ϫ SSC ϭ 150 mmol/L NaCl, 15 mmol/L Na and some demonstrated variable, focal, and generally mild features of transplant glomerulopathy as detected citrate, pH 7.0) and digested with proteinase K (1 g/mL; Sigma Chemical Co., St. Louis, MO, USA) in Tris-Cl by histological examination. Features of transplant glomerulopathy included increased glomerular lobularity, buffer (500 mmol/L NaCl, 10 mmol/L Tris, pH 8.0) for 40 minutes at 37ЊC. Several 0.5ϫ SSC washes were folthickening and splitting of peripheral capillary walls, and mesangial expansion. These changes were clearly present lowed by prehybridization for two hours in 50 L of prehybridization buffer (0.3 mol/L NaCl, 20 mmol/L Tris in four out of nine allograft nephrectomies, and were equivocally present in three additional kidneys in this pH 8.0, 5 mmol/L EDTA, 1ϫ Denhardt's solution, 10% dextran sulfate, 10 mmol/L DTT). The hybridizations group. Allograft kidneys demonstrated somewhat diffuse fibrosis of the cortical interstitium, associated with were started by adding 500,000 cpm of 35 S-labeled riboprobe in 50 L of prehybridization buffer and allowed to frequent and focally prominent infiltrates of mononuclear leukocytes in the interstitium. Muscular arteries proceed overnight at 50ЊC. After hybridization, sections were washed with 0.5ϫ SSC, treated with RNase A (20 demonstrated marked, typically concentric thickening of the intima by accumulations of matrix and spindle g/mL, 30 min at room temperature), washed in 2ϫ SSC (2 ϫ 2 min), followed by three high-stringency washes shaped cells. In several cases, there were additional features of superimposed acute rejection characterized by in 0.1ϫ SSC/0.1% Tween 20 (Sigma) at 50ЊC, and several 2ϫ SSC washes. After the tissue was dehydrated and air infiltration of the subendothelial space by mononuclear leukocytes, presumably due to diminished immunosuprecombinant protein (Fig. 1A) and to a 43 kD band in tissue [12] . Incubation with recombinant protein abolpression prior to anticipated allograft nephrectomy.
ished the staining by immunohistochemistry (Fig. 1 B, C) .
Characterization of the antibodies and SPARC
MAB-2 is a murine monoclonal IgG1 antibody directed expression in normal adult kidneys against SPARC peptide 1.1 (acids 3 to 23 of SPARC) [28] . Both antibodies resulted in comparable staining During the establishment of SPARC immunohistopatterns in methyl Carnoy's fixed, paraffin embedded chemistry we tested two antibodies against SPARC. The tissue sections. The staining pattern with the monoclonal murine monoclonal antibody directed against human, antibody MAB-2 was slightly superior to the results obrat, and bovine SPARC/osteonectin (AON-5031; Haematologic Technologies) antibody was characterized by tained with AON-5031. MAB-2 demonstrated a higher sensitivity and a lower background, as compared to AONWestern immunoblotting of purified, recombinant human SPARC (Fig. 1A) [16, 17] . Specific immunoreaction 5031. These differences were especially apparent in vascular smooth muscle cells and glomerular visceral epithewas localized to a 33 kD band of the non-glycoslyated 1D and 2B ). In the vasculature, arterial smooth muscle antibody AON-5031 were obtained from the manufacturer, and noticeable lot-to-lot differences in sensitivity cells (Figs. 1E and 2E ), adventitial fibroblasts, and collecting duct cells demonstrated widespread SPARC exin immunohistochemical studies of the same tissue were observed. Overall, the combined immunoreactive proppression (Figs. 1F and 2D ). Focal expression of SPARC was detected in distal tubular epithelium. Neointimal erties of AON-5031 and MAB-2 and the correlative localization of mRNA by in situ hybridization solidify the smooth muscle cells, routinely encountered in the arteriosclerosis of aging human kidneys, also demonstrated validity of these reagents as tools for localization of SPARC in human tissues. For these reasons, we relied on expression of SPARC (Fig. 2E) . SPARC-expressing endothelial cells were common in large and medium sized antibody MAB-2 for the principal findings of this study. arteries, whereas glomerular endothelium was not stained prising the visceral and parietal epithelium of developing for SPARC (Fig. 1 D, E, and Fig. 2D ). Interstitial fibroglomeruli ( Fig. 3 A, B) . In earlier glomerular structures blasts in the uninjured kidney were usually only weakly SPARC commonly became apparent in a polarized disand focally SPARC positive by our immunohistochemitribution at the base of immature, columnar appearing cal techniques (Figs. 1G and 2C ). There was possible focal podocytes, where they attach to the capillary basement staining of peritubular capillary endothelium, but we could membranes (Fig. 3B) . During glomerular maturation the not achieve sufficient resolution by light microscopy to pattern changed toward the diffuse cytoplasmic pattern exclude localization of SPARC in adjacent interstitial fiseen in adult visceral epithelial cells (Figs. 3A and 1D ). broblasts. The protein expression mirrored the mRNA Expression of SPARC by mesangial cells in differentiexpression detected by in situ hybridization (Figs. 1 and 2) . ated glomeruli was identified in 8 of 21 kidneys. Although SPARC expression during renal development these structures often failed to demonstrate immunohistochemically detectable SPARC expression, SPARC SPARC expression in developing glomeruli was most prominent at late stages of differentiation of cells comalso was expressed focally by differentiating epithelial cells comprising comma-and S-shaped bodies in about 4C, there were rare instances of possible SPARC expression by glomerular endothelial cells. half of the cases. There was no evidence of SPARC expression by structures involved in earlier stages of nephro- Figure 6 illustrates glomerular expression of SPARC and members of the PDGF ligand/receptor family in glogenesis such as metanephric blastema, tips of ureteric buds, or condensing vesicles.
meruli from a renal allograft with chronic allograft nephropathy. Particularly noteworthy is the colocalization SPARC was expressed in each of the extraglomerular tissue compartments in the fetal kidney (Fig. 3) . Tubular of SPARC and PDGF A chain in visceral epithelial cells; PDGF B chain expression is confined to the mesangium. expression of SPARC was generally confined to differentiated cells of the collecting duct system and pelvic uro- Figure 7 illustrates SPARC and PDGF expression in an artery with features of acute and chronic rejection, in thelium (Fig. 3 C, D) . In these sites, SPARC protein appeared polarized with localization primarily at the luwhich SPARC expression by medial and neointimal smooth muscle cells (expressing ␣ smooth muscle actin) minal surface of these cells. The basolateral cell surface at times also demonstrated localized expression of SPARC is congruent with PDGF A chain expression and in which SPARC expression by endothelial cells and some infil- (Fig. 3C) . Medial smooth muscle cells of arteries demonstrated widespread expression (Fig. 3E) . Prominent extrating leukocytes is congruent with expression by PDGF B-chain and PDGF␣ receptor by these cells. pression of SPARC by the adventitial fibroblast-like cells adjacent to muscular arteries also was identified. In the interstitium, SPARC was widely expressed by mesenchy-DISCUSSION mal cells likely corresponding to interstitial fibroblasts This study localized the expression of both SPARC both within the cortex and medulla (Fig. 3D) . As in adult protein and mRNA to glomeruli, collecting ducts, urokidney, sites of SPARC protein expression were coincithelium, interstitial cells, and arteries of developing as dent with sites of SPARC mRNA synthesis as detected well as mature human kidneys. These sites of SPARC by in situ hybridization (data not shown).
expression in humans generally, but not invariably, conform to previous observations obtained from rodent SPARC expression during human renal allograft rejection models of renal injury [10, 11, 13, 29] . Some differences with a prior published study localizing SPARC in In chronic allograft nephropathy, a prominent change human kidney were apparent in the present investigain SPARC expression became apparent. Noteworthy in tion. Mundlos et al described SPARC expression only this set of tissues was the prominent expression of in glomeruli in fetal human kidneys [30] . This stands in SPARC in the neointima of arteries with histologic feacontrast to the findings of SPARC expression in collecttures of chronic rejection (obliterative arteriopathy; Fig. ing ducts, urothelium, arteries, and interstitial cells re-4 A, B). Expression of SPARC by smooth muscle cells ported here. Our findings were made both on protein of the medial portions of the arterial wall persisted (Fig. and mRNA level and conform to findings in other mam-4 A, B). An increased number of SPARC positive intermalian systems (for example, rat and mouse) as well as stitial cells became detectable in areas of interstitial fito general observations in human fibrocytes and arterial brosis (Fig. 4E) . The distribution pattern in the intersticells reported by Porter et al [15] . The reagents utilized tium mirrored the distribution of smooth muscle actin both for in situ hybridization and immunocytochemistry positive interstitial myofibroblasts (compare Fig. 4 panin the study of Mundlos et al are distinct from those els E and F), which was further evidenced by double imutilized in our own study, and this may account for much munolabeling of these cells for actin and SPARC as ilof the difference. It is possible their reagents lacked the lustrated in Figure 5 . At sites of interstitial leukocytic sensitivity to detect extraglomerular expression. infiltrates, a high number of SPARC positive cells were
In the human glomerulus, the localization of constituscattered between infiltrating inflammatory cells. Howtive expression of SPARC to visceral epithelial cells is ever, a minority of interstitial leukocytes, expressing the of interest in view of the anti-proliferative properties of monocyte/macrophage differentiation marker CD68, could this molecule for cells in vitro. There is increasing evibe shown on replicate tissue sections to express SPARC dence that the glomerular visceral epithelial cell has an peptide as detected by immunohistochemistry (Fig. 5) .
extremely limited capacity for replication [31, 32] . ThereAdditionally, endothelium of peritubular capillaries fore, SPARC may contribute to the resistance to prolifercommonly demonstrated SPARC expression, especially ative stimuli in these cells. It is also of interest that we in areas of interstitial fibrosis (Fig. 4D) . A small subset of have previously localized PDGF A-chain expression to inflammatory cells, typically seen in lumina of peritubuthe human glomerular visceral epithelial cell [23] . A role lar capillaries, also expressed SPARC. Glomerular epifor SPARC in mediating renal injury as well as injury thelial cells demonstrated persistent expression of SPARC in other tissues is suggested in part by its ability to bind without clear change in its expression by other components of the glomerular tufts. As illustrated in Figure the growth factor PDGF and hence modulate signaling pathways regulated by this factor. However, the binding modulate the ability of PDGF-BB and PDGF-AB to interact with this receptor by virtue of its binding to the of SPARC to PDGF is thought to occur via the PDGF B-chain, and thus would affect only activities of the PDGF B-chain molecule [33] . We speculate that SPARC may modulate the response of parietal epithelial cells to PDGF heterodimers PDGF-BB and PDGF-AB, but not the PDGF-AA or PDGF A-chain per se [33] . Therefore, PDGF in glomerular injury, but a means to test this hypothesis in human cells is not currently available. we are uncertain whether any biological interaction results from the co-localization of these two molecules.
Mesangial expression of SPARC has been documented in the rodent both in vivo and in vitro. In rat mesangial The current study also demonstrates that SPARC is constitutively expressed by parietal epithelial cells, a cell cells, SPARC expression may be up-regulated by several growth factors including PDGF and FGF-2 [12]. In turn, type previously shown by us and others to be one in which constitutive expression of PDGF receptor ␤ (PDGFR␤) its up-regulated expression by mesangial cells has been correlated with resolution of the acute mesangial cell is found [34] . This is of particular interest in view of the studies by Raines et al, showing that SPARC can proliferation that occurs in the anti-Thy-1 mesangial pro- liferative glomerulonephritis model [12] . This is consiseach of these molecules typically is down-regulated in the healthy mature kidney, but may be re-expressed in tent with the observation that cultured mesenchymal cells, including mesangial cells, from SPARC deficient mice the course of mesangial proliferative injury and repair. This has suggested a paradigm where the biologic events exhibit increased rates of cell proliferation [35] . Again, it has been proposed that the association between SPARC and the molecular signals that direct these events occurring in the repair of glomerular injury represent a recaexpression and resolution of mesangial cell proliferation in the anti-Thy-1 model may reflect possible interruption pitulation of renal development [37] . The expression of SPARC has not yet been tested in human glomeruloof binding of PDGF B-chain to its receptors, an event that mediates earlier phases of injury in this model. This nephritis to evaluate whether this paradigm holds for this molecule as well. The evidence concerning SPARC study demonstrates that SPARC is occasionally expressed by human mesangial cells, most notably in the fetal kidexpression obtained from the anti-Thy-1 mesangial proliferative nephritis model indicates that the paradigm is ney. Our work and that of others has previously identified several molecules such as ␣-actin, PDGFR␤, PDGF true at least in the rat. We show in Figure 7 that, at least in chronic allograft nephropathy, mesangial expression B-chain, and p75 nerve growth factor receptor, that are expressed by mesangial cells at the same stages of develof PDGF B-chain may be up-regulated while glomerular SPARC expression remains confined to visceral epitheopment identified for SPARC [21, 36] . Expression of lial cells, similar to the expression pattern of PDGF some infiltrating inflammatory cells in areas of chronic fibrosing injury occurring as part of chronic allograft A-chain. Moreover, the autocrine loop effected by SPARC on cultured mesangial cells, via its induction of TGF-␤1 nephropathy. SPARC expression by interstitial cells is only focally and weakly detectable in the mature adult and collagen type I, is likely to prove significant in fibroproliferative disorders of the glomerulus [6, 7] .
kidney, but in the setting of chronic tubulointerstitial injury, this expression is dramatically up-regulated. SeThe second major finding of this study is the localization of SPARC to interstitial myofibroblast-like cells and rial labeling studies and double immunolabeling studies demonstrated that most SPARC-expressing interstitial in chronic injury states may modulate the effects of continued exposure to PDGF by these cells, either through cells also express ␣-smooth muscle actin. This last feature has led to consideration of these interstitial cells as myodirect anti-proliferative properties of SPARC or by the direct interference with the binding of PDGF to its recepfibroblasts [38] [39] [40] [41] . Accumulation of these cells has been clearly identified at sites of human and experimental tors. The induction of TGF-␤ by SPARC might be another important pathway involved in the regulation of tubulointerstitial injury, and there is recent evidence that their enumeration may be a particularly accurate progtubulointerstitial fibrosis [14] . SPARC was localized also to a minority of the infilnostic factor in studies of human diseases such as diabetes mellitus [41, 42] and membranous nephropathy [43] . It trating mononuclear leukocytes typically present in areas of chronic tubulointerstitial injury occurring as part of is also of note that these myofibroblast-like interstitial cells in the human express both PDGF ␣ and ␤ receptors chronic allograft nephropathy. SPARC previously has been identified in monocytes/macrophages in wound heal-[25, 44], making them likely to be responsive to stimulation by heterodimers containing the PDGF B-chain. Ining in experimental systems. However, the specific activities of leukocyte SPARC are not currently understood. deed, Tang et al have demonstrated direct stimulation of proliferation and collagen production by myofibroblast-SPARC has been shown to mediate some responses of human monocytes to injury, such as the production of like renal interstitial cells in rats in vivo exposed to infusions of PDGF B-chain [45] . In this site, it seems likely matrix metalloproteinases [46] . This suggests the possibility of an autocrine stimulatory pathway for these efthat up-regulated SPARC production by interstitial cells in renal interstitial fibrosis and in renal vascular injury. Kidney Int fector cells, which are commonly present in various renal 50:1978-1989, 1996 diseases. hypothesis that the effects exerted by SPARC in these
